{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:12:38Z","timestamp":1724454758586},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>At the time of benign gynecological surgery, a prophylactic salpingo-oophorectomy or salpingectomy is increasingly being performed concurrently to reduce the risk of future ovarian and fallopian tube cancer. We herein describe a case of hereditary breast and ovarian cancer syndrome in which a hysterectomy and bilateral adnexectomy were performed with a preoperative diagnosis of benign tumor. A detailed pathological examination revealed occult fallopian tube cancer, and additional staging surgery provided an accurate pathology diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 72-year-old Japanese woman with a past history of breast cancer underwent a hysterectomy and bilateral oophoro-salpingectomy for the preoperative diagnosis of uterine myoma and a right para-ovarian cyst. In the detailed pathological examination, high-grade serous carcinoma of the right fallopian tube was detected incidentally, and a subsequent staging laparotomy confirmed single para-aortic lymph node metastasis. Furthermore, a mutation in germline <jats:italic>BRCA<\/jats:italic>2 was detected postoperatively, and the patient was finally diagnosed with hereditary breast and ovarian cancer syndrome. She was diagnosed with fallopian tube cancer International Federation of Gynecology and Obstetrics Stage IIIA1(i) and started on adjuvant therapy (six courses of paclitaxel and carboplatin followed by maintenance therapy with olaparib), and 18\u00a0months after surgery, she was free of disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is a case of fallopian tube cancer that was diagnosed incidentally and then accurately staged with additional advanced staging surgery. Even in the absence of grossly malignant findings, a detailed pathological search of the fallopian tubes and accurate staging surgery are important to make the necessary treatment decisions for the patient.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04095-6","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:01:51Z","timestamp":1692316911000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Hikaru","family":"Murakami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoe","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruri","family":"Nishie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Ohmichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"4095_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","volume":"14","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150.","journal-title":"BMC Womens Health"},{"key":"4095_CR2","first-page":"625","volume":"3","author":"K Mehra","year":"2011","unstructured":"Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011;3:625\u201334.","journal-title":"Front Biosci (Elite Ed)"},{"key":"4095_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/pin.12419","volume":"66","author":"N Nishida","year":"2016","unstructured":"Nishida N, Murakami F, Higaki K. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer. Pathol Int. 2016;66:337\u201342.","journal-title":"Pathol Int"},{"key":"4095_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jog.12550","volume":"41","author":"F Zeppernick","year":"2015","unstructured":"Zeppernick F, Meinhold-Heerlein I, Shih IM. Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma\u2014an update. J Obstet Gynaecol Res. 2015;41:6\u201311.","journal-title":"J Obstet Gynaecol Res"},{"key":"4095_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/01.AOG.0000459871.88564.09","volume":"125","author":"Committee opinion no 620","year":"2015","unstructured":"Committee opinion no 620. Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015;125:279\u201381.","journal-title":"Obstet Gynecol"},{"key":"4095_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/AOG.0000000000002521","volume":"131","author":"VB Desai","year":"2018","unstructured":"Desai VB, Wright JD, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, Lin H, Gross CP, Xu X. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. Obstet Gynecol. 2018;131:642\u201351.","journal-title":"Obstet Gynecol"},{"key":"4095_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5468\/ogs.20199","volume":"64","author":"G Yadav","year":"2021","unstructured":"Yadav G, Rao M, Goyal SB, Singh P, Kathuria P, Gothwal M. Risk of incidental genital tract malignancies at the time of myomectomy and hysterectomy for benign conditions. Obstet Gynecol Sci. 2021;64:209\u201315.","journal-title":"Obstet Gynecol Sci"},{"key":"4095_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejso.2019.09.002","volume":"46","author":"A Cheng","year":"2020","unstructured":"Cheng A, Li L, Wu M, Lang J. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46:139\u201347.","journal-title":"Eur J Surg Oncol"},{"key":"4095_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1, 2023. Breast, Ovarian, and Pancreatic. Version 1, 2023."},{"key":"4095_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"JB Trimbos","year":"2003","unstructured":"Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95:113\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"4095_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/COC.0b013e318134ee6f","volume":"31","author":"DS Dizon","year":"2008","unstructured":"Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Am J Clin Oncol. 2008;31:39\u201342.","journal-title":"Am J Clin Oncol"},{"key":"4095_CR12","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"4095_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"4095_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Maenpaa J, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"4095_CR15","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1001\/jama.1983.03340220040030","volume":"250","author":"RC Young","year":"1983","unstructured":"Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072\u20136.","journal-title":"JAMA"},{"key":"4095_CR16","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/1097-0142(20001115)89:10<2076::AID-CNCR7>3.0.CO;2-V","volume":"89","author":"M Baekelandt","year":"2000","unstructured":"Baekelandt M, JorunnNesbakken A, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. Cancer. 2000;89:2076\u201384.","journal-title":"Cancer"},{"key":"4095_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1006\/gyno.2002.6636","volume":"85","author":"T Le","year":"2002","unstructured":"Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351\u20135.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4095_CR18","first-page":"15","volume":"20","author":"S Inoue","year":"2020","unstructured":"Inoue S, Ohmori M, Kimura A, Takahashi H, Nakayama Y, Ichikawa D, Nakagomi S, Yagasaki H, Nakane T. Importance of pre-counseling for hereditary breast cancer. J Heredit Tumors. 2020;20(3):15\u20139.","journal-title":"J Heredit Tumors"},{"key":"4095_CR19","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402\u201316.","journal-title":"JAMA"},{"key":"4095_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","volume":"4","author":"MS Yates","year":"2011","unstructured":"Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early-stage ovarian cancers in BRCA1\/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011;4:463\u201370.","journal-title":"Cancer Prev Res (Phila)"},{"key":"4095_CR21","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","volume":"32","author":"ME Sherman","year":"2014","unstructured":"Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014;32:3275\u201383.","journal-title":"J Clin Oncol"},{"key":"4095_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10147-019-01456-4","volume":"24","author":"H Nomura","year":"2019","unstructured":"Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S. Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan. Int J Clin Oncol. 2019;24:1105\u201310.","journal-title":"Int J Clin Oncol"},{"key":"4095_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2016.00108","volume":"6","author":"SH George","year":"2016","unstructured":"George SH, Garcia R, Slomovitz BM. Ovarian cancer: the fallopian tube as the site of origin and opportunities for prevention. Front Oncol. 2016;6:108.","journal-title":"Front Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04095-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:36:29Z","timestamp":1700591789000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4095"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04095-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper was approved by the Ethics Committee of Osaka Medical and Pharmaceutical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}